Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer: a Single-center, Single-arm, Phase II Clinical Trial

NCT06103617 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT06103617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06103617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer: a Single-center, Single-arm, Phase II Clinical Trial
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
November 15, 2023
Completion date
June 1, 2025
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, recurrent cancer